miR-199b-5p directly targets PODXL and DDR1 and decreased levels of miR-199b-5p correlate with elevated expressions of PODXL and DDR1 in acute myeloid leukemia

American Journal of Hematology

Volumn 87, Issue 4, 2012, Pages 442-446

  Favreau, Amanda J ^a,b   Cross, Erin L ^b   Sathyanarayana, Pradeep ^a,b,c  

^a UNIVERSITY OF MAINE   (United States)

^b Maine Medical Center Research Institute   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; DISCOIDIN DOMAIN RECEPTOR 1; MICRORNA; MIR 199B 5P; PODOCALYXIN; RECEPTOR; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ACUTE GRANULOCYTIC LEUKEMIA; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LETTER; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; VALIDATION STUDY;

3' UNTRANSLATED REGIONS; BONE MARROW; COLLAGEN TYPE IV; GENE EXPRESSION REGULATION, LEUKEMIC; GENE SILENCING; GENETIC VECTORS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIALOGLYCOPROTEINS; TRANSFECTION; UP-REGULATION;

EID: 84858285411     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23129     Document Type: Letter

References (26)

1. Cammarata G, Augugliaro L, Salemi D, et al. Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol 2010; 85: 331-339.
2. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368: 1894-1907.
3. Nielsen JS, McNagny KM. The role of podocalyxin in health and disease. J Am Soc Nephrol 2009; 20: 1669-1676.
4. Riccioni R, Calzolari A, Biffoni M, et al. Podocalyxin is expressed in normal and leukemic monocytes. Blood Cells Mol Dis 2006; 37: 218-225.
5. Kelley TW, Huntsman D, McNagny KM, et al. Podocalyxin: a marker of blasts in acute leukemia. Am J Clin Pathol 2005; 124: 134-142.
6. Sizemore S, Cicek M, Sizemore N, et al. Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res 2007; 67: 6183-6191.
7. Agbor TA, Demma ZC, Mumy KL, et al. The ERM protein, Ezrin, regulates neutrophil transmigration by modulating the apical localization of MRP2 in response to the SipA effector protein during Salmonella Typhimurium infection. Cell Microbiol 2011; 13: 2007-2021.
8. Larrucea S, Butta N, Arias-Salgado EG, et al. Expression of podocalyxin enhances the adherence, migration, and intercellular communication of cells. Exp Cell Res 2008; 314: 2004-2015.
9. Sathyanarayana P, Menon MP, Bogacheva O, et al. Erythropoietin modulation of podocalyxin and a proposed erythroblast niche. Blood 2007; 110: 509-518.
10. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
11. O'Connell RM, Chaudhuri AA, Rao DS, et al. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci U S A 107: 14235-14240.
12. Kuchen S, Resch W, Yamane A, et al. Regulation of microRNA expression and abundance during lymphopoiesis. Immunity 32: 828-839.
13. Ooi AG, Sahoo D, Adorno M, et al. MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. Proc Natl Acad Sci U S A 2010; 107: 21505-21510.
14. Havelange V, Stauffer N, Heaphy CC, et al. Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer 2011; 117: 4696-4706.
15. Dixon-McIver A, East P, Mein CA, et al. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One 2008; 3: e2141.
16. Marcucci G, Mrozek K, Radmacher MD, et al. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011; 117: 1121-1129.
17. Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183-3189.
18. Yoshimura T, Matsuyama W, Kamohara H. Discoidin domain receptor 1: a new class of receptor regulating leukocyte-collagen interaction. Immunol Res 2005; 31: 219-230.
19. Yang SH, Baek HA, Lee HJ, et al. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas. Oncol Rep 2010 24: 311-319.
20. Park HS, Kim KR, Lee HJ, et al. Overexpression of discoidin domain receptor 1 increases the migration and invasion of hepatocellular carcinoma cells in association with matrix metalloproteinase. Oncol Rep 2007; 18: 1435-1441.
21. Ram R, Lorente G, Nikolich K, et al. Discoidin domain receptor-1a (DDR1a) promotes glioma cell invasion and adhesion in association with matrix metalloproteinase-2. J Neurooncol 2006; 76: 239-248.
22. Doyonnas R, Kershaw DB, Duhme C, et al. Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J Exp Med 2001; 194: 13-27.
23. Gross O, Beirowski B, Harvey SJ, et al. DDR1-deficient mice show localized subepithelial GBM thickening with focal loss of slit diaphragms and proteinuria. Kidney Int 2004; 66: 102-111.
24. Shah MY, Licht JD. DNMT3A mutations in acute myeloid leukemia. Nat Genet 43: 289-290.
25. Garzia L, Andolfo I, Cusanelli E, et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One 2009; 4: e4998.
26. Sathyanarayana P, Houde E, Marshall D, et al. CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools. Blood 2009; 113: 4955-4962.